Literature DB >> 626989

Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate.

A Vecchi, M Cairo, A Mantovani, M Sironi, F Spreafico.   

Abstract

A comparative investigation of the antineoplastic activity of adriamycin and its derivative, N-trifluoroacetyladriamycin-14-valerate (AD 32), was conducted in murine tumor models employing different treatment schedules and injection routes. In all conditions tested, ie, ascitic and disseminated L1210 leukemia, ascitic LSTRA lymphoma, and advanced Lewis lung carcinoma, AD 32 was significantly more effective in terms of lifespan prolongation and induction of cures than optimal adriamycin treatments. As with adriamycin, AD 32 was ineffective on ic transplanted L1210 leukemia.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 626989

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  8 in total

Review 1.  Valrubicin.

Authors:  S V Onrust; H M Lamb
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

2.  Comparative effects of adriamycin and DNA-non-binding analogues on DNA, RNA, and protein synthesis in vitro.

Authors:  M Israel; J M Idriss; Y Koseki; V K Khetarpal
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Influence of scheduling on therapeutic and toxic effect of AMSA in Lewis lung carcinoma.

Authors:  C Greco; G Zupi; G Badaracco
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

4.  Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C]-labeled AD 32 administration. Evidence for tissue aglycone formation.

Authors:  M Israel; A M Karkowsky; V K Khetarpal
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study.

Authors:  T W Sweatman; R F Parker; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines.

Authors:  H B Niell; R F Hunter; H G Herrod; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Pharmacologic studies with radiolabeled N-trifluoroacetyladriamycin-14-valerate (AD 32). Comparison of total anthracycline fluorescence and radioactivity in mouse serum and urine.

Authors:  M Israel; A M Karkowsky; W J Pegg
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

8.  Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles.

Authors:  Nirupama Sabnis; Maya Nair; Mervyn Israel; Walter J McConathy; Andras G Lacko
Journal:  Int J Nanomedicine       Date:  2012-02-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.